Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Amgen Call Center 866-572-6436
medinfo@amgen.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors
Back

A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors

Recruiting

Open to: ALL

Age: 18.0 - 100.0

Sutton London

Medical Conditions

Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.

The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2022 Aug 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : AMG 193: Orally via tablet

Intervention Arm Group : Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration;Part 1c, Phase 1: AMG 193 Monotherapy Dose Expansion;Part 1e, Phase 1: AMG 193 Monotherapy Dose Expansion;Part 1f, Phase 1: AMG 193 Monotherapy Dose Expansion;Part 1g, Phase 1: AMG 193 Monotherapy Dose Expansion;Part 1h, Phase 1: AMG 193 Monotherapy Dose Expansion;Part 1i, Phase 1: AMG 193 Dose Optimization;Part 1j, Phase 1: AMG 193 DSPS Substudy (US Sites Only);Part 1k, Phase 1: AMG 193 Food Effect Substudy (US Sites Only);Part 1l, Phase 1: AMG 193 Monotherapy Dose Expansion;Part 1m, Phase 1: AMG 193 Monotherapy Dose Expansion;Part 2a, Phase 1: AMG 193 Dose Exploration + Docetaxel;Part 2b, Phase 1: AMG 193 + Docetaxel Dose Expansion;Part 3: AMG 193 Phase 2;

Intervention Type : DRUG
Intervention Description : Docetaxel: Intravenous infusion

Intervention Arm Group : Part 2a, Phase 1: AMG 193 Dose Exploration + Docetaxel;Part 2b, Phase 1: AMG 193 + Docetaxel Dose Expansion;

Intervention Type : DRUG
Intervention Description : Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.

Intervention Arm Group : Part 1j, Phase 1: AMG 193 DSPS Substudy (US Sites Only);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Royal Marsden Hospital
    Sutton
    SM2 5PT
  • Sarah Cannon Research Institute UK
    London
    W1G 6AD

Amgen Call Center 866-572-6436
medinfo@amgen.com



The study is sponsored by Amgen



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05094336
Last updated 09 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top